Exit Multiples and Clinical Evidence
Regulation rarely moves at the speed of capital formation. The proliferation of privately financed peptide clinics illustrates a recurring structural ...
The Subscription Clinic Economy
The waiting room has begun to resemble a product funnel. The growth of subscription-based peptide clinics signals a deeper transformation ...
When Capital Meets Molecules
Capital rarely waits for clinical consensus. The rapid expansion of direct‑to‑consumer peptide clinics reflects a deeper convergence of investor time ...
Earnings Calls, Appetite Signals, and the Future of Benefits
The quarterly earnings call turned unexpectedly clinical. Analysts asked about weight loss drugs. Employers responding to GLP‑1 adoption pressures increasingly ...
The Workforce Becomes a Metabolic Portfolio
The quiet revolution began in the cafeteria. Employers analyzing aggregate nutrition data alongside GLP‑1 prescription trends are discovering that pharmacologic ...
Metabolic Risk as Corporate Strategy
The spreadsheet was supposed to be about premiums. Instead, it became a referendum on metabolism. Across boardrooms and benefits committees, ...
The Governance Problem Hidden Inside a Weight Loss Drug
Innovation often arrives disguised as inevitability. Retatrutide’s trajectory through clinical trials, investor speculation, and policy discourse suggests a future in ...
The Politics of Therapeutic Legitimacy
Medicine prefers to imagine itself as insulated from politics. Reality is less accommodating. The recent association of peptide deregulation discourse ...
Triple Agonists and the Rewriting of Care Pathways
Some drugs change physiology. Others change the grammar of healthcare economics. Retatrutide, the experimental triple agonist drawing sustained attention across ...
Retatrutide and the Acceleration of Metabolic Medicine
The molecule arrived before the consensus did. Retatrutide — the triple agonist now circulating through clinical trial discourse, investor decks, ...
Markets, Memory, and the Messenger
Policy announcements can behave like speculative assets. The recent prominence of Secretary Robert F. Kennedy Jr. in discussions about peptide ...
How Sterile Processing Standards Influence Surgical Safety
Sterile processing standards shape surgical safety, reduce infection risk, support compliance, and strengthen patient outcomes in modern healthcare systems.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more